Home / News / News & Updates / Disparities in Public Cancer Drug Funding Disparities in Public Cancer Drug Funding "Not All Canadian Cancer Patients Are Equal - Disparities in Public Cancer Drug Funding across Canada" Ceilidh MacPhail and Stephanie Snow Abstract: Canada lacks a national drug insurance plan. The home province or territory of a patient determines which cancer drugs are available on the public formulary, who is eligible for public coverage and what portion of the financial burden of cancer care falls to the individual. This narrative review describes the current interprovincial disparities in access to cancer drugs across Canada. Health technology assessment (HTA) of drugs at a provincial and territory level is a closed process, does not necessarily follow the recommendations of national HTA and leads to further delays in drug access. The public coverage of take‐home cancer drugs (THCDs) in Ontario and the Atlantic provinces is often fragmented, unnecessarily complex and a barrier to cancer drug access. Policy solutions to address inter‐provincial formulary variation and poor access to THCDs are discussed. FULL ARTICLE: curroncol-29-00166-(1).pdf News News & Updates Current News February 2024 Newsletter In this Issue: Nova Scotia Screening Program Announced! Lung Ambition Awards Opportunity Listen to our Lung Cancer Voices Podcast Upcoming Events Read More November 2023 Newsletter In this issue: LCAM Activities November 2023 Newsletter Read More Questions To Ask Clinical Trials Share Your Story Community Activities Make A Donation Peer to Peer Network
Home / News / News & Updates / Disparities in Public Cancer Drug Funding Disparities in Public Cancer Drug Funding "Not All Canadian Cancer Patients Are Equal - Disparities in Public Cancer Drug Funding across Canada" Ceilidh MacPhail and Stephanie Snow Abstract: Canada lacks a national drug insurance plan. The home province or territory of a patient determines which cancer drugs are available on the public formulary, who is eligible for public coverage and what portion of the financial burden of cancer care falls to the individual. This narrative review describes the current interprovincial disparities in access to cancer drugs across Canada. Health technology assessment (HTA) of drugs at a provincial and territory level is a closed process, does not necessarily follow the recommendations of national HTA and leads to further delays in drug access. The public coverage of take‐home cancer drugs (THCDs) in Ontario and the Atlantic provinces is often fragmented, unnecessarily complex and a barrier to cancer drug access. Policy solutions to address inter‐provincial formulary variation and poor access to THCDs are discussed. FULL ARTICLE: curroncol-29-00166-(1).pdf News News & Updates Current News February 2024 Newsletter In this Issue: Nova Scotia Screening Program Announced! Lung Ambition Awards Opportunity Listen to our Lung Cancer Voices Podcast Upcoming Events Read More November 2023 Newsletter In this issue: LCAM Activities November 2023 Newsletter Read More Questions To Ask Clinical Trials Share Your Story Community Activities Make A Donation Peer to Peer Network